Literature DB >> 12182253

A randomized, double-blind, placebo-controlled comparison of the analgesic efficacy, onset of action, and tolerability of ibuprofen arginate and ibuprofen in postoperative dental pain.

Peter Black1, Mitchell B Max, Paul Desjardins, Thomas Norwood, Alfredo Ardia, Teresa Pallotta.   

Abstract

BACKGROUND: Because of its enhanced pharmacokinetic characteristics, ibuprofen arginate might be expected to provide faster pain relief than standard ibuprofen formulations in patients experiencing acute pain.
OBJECTIVE: This study assessed the analgesic efficacy, speed of onset, and tolerability of ibuprofen arginate compared with a commercially available form of ibuprofen in patients with postoperative dental pain.
METHODS: Patients were randomized to receive ibuprofen arginate 200 or 400 mg, ibuprofen 200 or 400 mg, or placebo in this multicenter, double-blind, double-dummy, parallel-group trial. Patients were observed for 6 hours after administration of a single dose of study medication. A repeated-dose, open-label phase followed. Pain intensity and pain relief were measured using traditional verbal descriptor scales; onset of analgesia was assessed using 2 stopwatches to measure the time to achievement of specific pain relief criteria.
RESULTS: A total of 498 patients (219 men, 279 women; mean age, 21.5 years) participated in this study. Baseline pain was moderate in 388 patients (78%) and severe in 110 patients (22%). Meaningful pain relief was reached after a median of 29 and 28 minutes with ibuprofen arginate 200 and 400 mg, respectively, and after 52 and 44 minutes with ibuprofen 200 and 400 mg, respectively (all, P < 0.05). The percentages of patients who achieved meaningful pain relief within the first hour after treatment were 77.6% and 83.7% for ibuprofen arginate 200 and 400 mg, respectively, 61.0% and 63.0% for ibuprofen 200 and 400 mg, respectively, and 39.8% for placebo. The differences between ibuprofen arginate and ibuprofen were statistically significant (both doses, P < 0.05). Significantly greater numbers of patients achieved meaningful pain relief with ibuprofen arginate 400 mg compared with placebo from 20 minutes through 6 hours and with ibuprofen arginate 200 mg from 30 minutes through 6 hours (P < 0.05). Compared with placebo, a greater number of patients achieved meaningful pain relief with ibuprofen 400 mg from 45 minutes through 6 hours; with ibuprofen 200 mg. the corresponding interval was from I through 6 hours. After the first hour, pain reduction was similar for the similar doses of the 2 ibuprofen preparations. Median remedication times with both doses of ibuprofen arginate were similar to those with both doses of ibuprofen, ranging from 4.0 to 5.2 hours. Adverse-event profiles were similar between the 2 active medications.
CONCLUSIONS: Ibuprofen arginate was effective in this population of patients experiencing moderate to severe pain after surgical extraction of > or = 1 impacted third molar, with 16 to 24 minutes' faster time to meaningful pain relief than with ibuprofen. The 2 formulations had similar tolerability profiles.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12182253     DOI: 10.1016/s0149-2918(02)80020-0

Source DB:  PubMed          Journal:  Clin Ther        ISSN: 0149-2918            Impact factor:   3.393


  17 in total

Review 1.  Single dose oral ibuprofen for acute postoperative pain in adults.

Authors:  Christopher Derry; Sheena Derry; R Andrew Moore; Henry J McQuay
Journal:  Cochrane Database Syst Rev       Date:  2009-07-08

2.  [Effectiveness and time to onset of pregabalin in patients with neuropathic pain].

Authors:  R Freynhagen; P Busche; C Konrad; M Balkenohl
Journal:  Schmerz       Date:  2006-08       Impact factor: 1.107

3.  Pain management for dentists: the role of ibuprofen.

Authors:  Alessandro Pozzi; Luca Gallelli
Journal:  Ann Stomatol (Roma)       Date:  2012-04-15

4.  A randomized, double-blind, parallel trial comparing capsaicin nasal spray with placebo in subjects with a significant component of nonallergic rhinitis.

Authors:  Jonathan A Bernstein; Benjamin P Davis; Jillian K Picard; Jennifer P Cooper; Shu Zheng; Linda S Levin
Journal:  Ann Allergy Asthma Immunol       Date:  2011-06-29       Impact factor: 6.347

5.  A comparative study of the pharmacokinetics of ibuprofen arginate versus dexibuprofen in healthy volunteers.

Authors:  Belén Sádaba; Miguel A Campanero; Maria Jose Muñoz-Juarez; Isabel Gil-Aldea; Emilio García-Quetglas; Antonio Esteras; Jose R Azanza
Journal:  Eur J Clin Pharmacol       Date:  2006-08-15       Impact factor: 2.953

6.  Effect of ibuprofen on cyclooxygenase and nitric oxide synthase of gastric mucosa: correlation with endoscopic lesions and adverse reactions.

Authors:  Sonia Gallego-Sandín; Jesús Novalbos; Aránzazu Rosado; Javier P Gisbert; María-Angeles Gálvez-Múgica; Antonio G García; José María Pajares; Francisco Abad-Santos
Journal:  Dig Dis Sci       Date:  2004-09       Impact factor: 3.199

7.  Efficacy and safety of Ibuprofen arginine in the treatment of primary dysmenorrhoea.

Authors:  Camil Castelo-Branco; Gemma Casals; Javier Haya; María Jesús Cancelo; José Manasanch
Journal:  Clin Drug Investig       Date:  2004       Impact factor: 2.859

8.  Analgesia with ibuprofen arginate versus conventional ibuprofen for patients with dysmenorrhea: a crossover trial.

Authors:  Donald R Mehlisch; Alfredo Ardia; Teresa Pallotta
Journal:  Curr Ther Res Clin Exp       Date:  2003-06

9.  Onset of analgesia with sodium ibuprofen, ibuprofen acid incorporating poloxamer and acetaminophen--a single-dose, double-blind, placebo-controlled study in patients with post-operative dental pain.

Authors:  Stephen Daniels; Sandie Reader; Phillip Berry; Michael Goulder
Journal:  Eur J Clin Pharmacol       Date:  2009-02-28       Impact factor: 2.953

Review 10.  Clinical trial designs and models for analgesic medications for acute pain in neonates, infants, toddlers, children, and adolescents: ACTTION recommendations.

Authors:  Gary A Walco; Ernest A Kopecky; Steven J Weisman; Jennifer Stinson; Bonnie Stevens; Paul J Desjardins; Charles B Berde; Elliot J Krane; Kanwaljeet J S Anand; Myron Yaster; Carlton D Dampier; Robert H Dworkin; Ian Gilron; Anne M Lynn; Lynne G Maxwell; Srinivasa Raja; Bernard Schachtel; Dennis C Turk
Journal:  Pain       Date:  2018-02       Impact factor: 7.926

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.